News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pozen, Inc. Reports PA32540 / PA8140 Updates and Second Quarter 2012 Financial Results
August 1, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
·
2 min read
·
Gabrielle Masson
Bankruptcy
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
August 28, 2026
·
1 min read
·
Michael Gibney
Antibody-drug conjugate (ADC)
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
August 28, 2026
·
1 min read
·
Tristan Manalac
Immunology and inflammation
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
August 28, 2026
·
2 min read
·
Tristan Manalac
